Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Guido J. R. Zaman"'
Autor:
Elisa Zanini, Nicole Forster-Gross, Felix Bachmann, Adrian Brüngger, Paul McSheehy, Karine Litherland, Karin Burger, Anna C. Groner, Mila Roceri, Luc Bury, Martin Stieger, Nicole Willemsen-Seegers, Jos de Man, Diep Vu-Pham, Helma W. E. van Riel, Guido J. R. Zaman, Rogier C. Buijsman, Laurenz Kellenberger, Heidi A. Lane
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThreonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) are common essential kinases that collaborate in activating the spindle assembly checkpoint (SAC) at the kinetochore, ensuring appropriate chromosome alignment and segregation pr
Externí odkaz:
https://doaj.org/article/cf9a84a3e06f4b3a99f2975a86de17db
Autor:
Gisele Nishiguchi, Lauren G. Mascibroda, Sarah M. Young, Elizabeth A. Caine, Sherif Abdelhamed, Jeffrey J. Kooijman, Darcie J. Miller, Sourav Das, Kevin McGowan, Anand Mayasundari, Zhe Shi, Juan M. Barajas, Ryan Hiltenbrand, Anup Aggarwal, Yunchao Chang, Vibhor Mishra, Shilpa Narina, Melvin Thomas, Allister J. Loughran, Ravi Kalathur, Kaiwen Yu, Suiping Zhou, Xusheng Wang, Anthony A. High, Junmin Peng, Shondra M. Pruett-Miller, Danette L. Daniels, Marjeta Urh, Anang A. Shelat, Charles G. Mullighan, Kristin M. Riching, Guido J. R. Zaman, Marcus Fischer, Jeffery M. Klco, Zoran Rankovic
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Molecular-glue degraders are small molecules that induce a specific interaction between an E3 ligase and a target protein, resulting in the target proteolysis. The discovery of molecular glue degraders currently relies mostly on screening ap
Externí odkaz:
https://doaj.org/article/93a742dfa7284effac1e877a18d0d84e
Autor:
Valentina Cordo’, Mariska T. Meijer, Rico Hagelaar, Richard R. de Goeij-de Haas, Vera M. Poort, Alex A. Henneman, Sander R. Piersma, Thang V. Pham, Koichi Oshima, Adolfo A. Ferrando, Guido J. R. Zaman, Connie R. Jimenez, Jules P. P. Meijerink
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
No targeted therapy has been approved yet for the treatment of T cell acute lymphoblastic leukemia. Here the authors show that unbiased phosphoproteomic profiling can identify targetable kinases and guide the design of personalized combination treatm
Externí odkaz:
https://doaj.org/article/c5d14de3e81a4a469e7a8481cdc98225
Autor:
Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Martine B. W. Prinsen, Yvonne Grobben, Tessa J. J. de Bitter, Antoon M. van Doornmalen, Janneke J. T. M. Melis, Joost C. M. Uitdehaag, Yugo Narumi, Yusuke Kawase, Jeroen A. D. M. de Roos, Nicole Willemsen-Seegers, Guido J. R. Zaman
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
During the last two decades, kinase inhibitors have become the major drug class for targeted cancer therapy. Although the number of approved kinase inhibitors increases rapidly, comprehensive in vitro profiling and comparison of inhibitor activities
Externí odkaz:
https://doaj.org/article/8a2b28555c90401aa5082f21d4b9f7f8
Autor:
Yvonne Grobben, Jos de Man, Antoon M. van Doornmalen, Michelle Muller, Nicole Willemsen-Seegers, Diep Vu-Pham, Winfried R. Mulder, Martine B. W. Prinsen, Joeri de Wit, Jan Gerard Sterrenburg, Freek van Cauter, Judith E. den Ouden, Anne M. van Altena, Leon F. Massuger, Joost C. M. Uitdehaag, Rogier C. Buijsman, Guido J. R. Zaman
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies. We describ
Externí odkaz:
https://doaj.org/article/67d223be9e3a4daabf3fe18bdc0d30fd
Autor:
Seong Jang, Bill Strickland, Lynda Finis, Jeffrey J. Kooijman, Janneke J. T. M. Melis, Guido J. R. Zaman, Jan Van Tornout
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:491-499
Vascular endothelial growth factor receptor 2 (VEGFR2), a key regulator of tumor angiogenesis, is highly expressed across numerous tumor types and has been an attractive target for anti-cancer therapy. However, clinical application of available VEGFR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce7b9c2b2e53d428752de2d3e47010e0
https://doi.org/10.1007/s00280-023-04534-7
https://doi.org/10.1007/s00280-023-04534-7
Autor:
Yvonne Grobben, Judith E. den Ouden, Cristina Aguado, Anne M. van Altena, Aletta D. Kraneveld, Guido J. R. Zaman
Publikováno v:
Cancers
Volume 15
Issue 3
Pages: 893
Cancers, 15, 3
Cancers, 15
Volume 15
Issue 3
Pages: 893
Cancers, 15, 3
Cancers, 15
The molecular mechanisms contributing to immune suppression in ovarian cancer are not well understood, hampering the successful application of immunotherapy. Amino acid-metabolizing enzymes are known to contribute to the immune-hostile environment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bad2cfb6729c4bf883e9804eca19d0c
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Autor:
Neil T Conlon, John Crown, Jeffrey J. Kooijman, Guido J. R. Zaman, Lisa D. Eli, Suzanne J.C. van Gerwen, Winfried R. Mulder, Alshad S. Lalani, Denis M. Collins, Irmina Diala
Publikováno v:
British Journal of Cancer
BackgroundHuman epidermal growth factor 2 (HER2/ERBB2) is frequently amplified/mutated in cancer. The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive breast cancer. Direct comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23aa8bc1e4fb66f76536c89006cc4784
https://doi.org/10.1038/s41416-020-01257-x
https://doi.org/10.1038/s41416-020-01257-x
Autor:
Joost C M Uitdehaag, Jeroen A D M de Roos, Antoon M van Doornmalen, Martine B W Prinsen, Jill A P Spijkers-Hagelstein, Judith R F de Vetter, Jos de Man, Rogier C Buijsman, Guido J R Zaman
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0125021 (2015)
The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance. Preferably, drug combinations are synergistic rather than additive, and, ideally, drug combinat
Externí odkaz:
https://doaj.org/article/ef8b227b2f6d4dc1b37d97ccc9facfc1
Autor:
Valentina, Cordo', Mariska T, Meijer, Rico, Hagelaar, Richard R, de Goeij-de Haas, Vera M, Poort, Alex A, Henneman, Sander R, Piersma, Thang V, Pham, Koichi, Oshima, Adolfo A, Ferrando, Guido J R, Zaman, Connie R, Jimenez, Jules P P, Meijerink
Publikováno v:
Nature communications. 13(1)
Protein kinase inhibitors are amongst the most successful cancer treatments, but targetable kinases activated by genomic abnormalities are rare in T cell acute lymphoblastic leukemia. Nevertheless, kinases can be activated in the absence of genetic d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cedad4cdb898fb26ff68cbdf8b63a35b
https://pubmed.ncbi.nlm.nih.gov/35217681
https://pubmed.ncbi.nlm.nih.gov/35217681